New data show sustained responses for patients with non-Hodgkin lymphoma, a form of blood cancer

OHSU physician-researcher presents updated gene transfer therapy data at national hematology conference, publishes study results in The New England Journal of Medicine

By Amanda Gibbs December 03, 2018 Portland, Oregon

Downloads

Richard Maziarz, M.D.

Richard Maziarz, M.D., medical director of the adult blood and marrow stem cell transplant and cellular therapy program in the OHSU Knight Cancer Institute. (OHSU/Kristyna Wentz-Graff)

Richard Maziarz, M.D.

Richard Maziarz, M.D., medical director of the adult blood and marrow stem cell transplant and cellular therapy program in the OHSU Knight Cancer Institute. (OHSU/Kristyna Wentz-Graff)

Cellular therapy program

Richard Maziarz, M.D., medical director of the adult blood and marrow stem cell transplant and cellular therapy program at the OHSU Knight Cancer Institute. Researchers in the program are looking for new ways to treat lethal cancers such as skin cancer. (OHSU/Kristyna Wentz-Graff)

Richard Maziarz, M.D. (OHSU)

Richard Maziarz, M.D.

Richard Maziarz, M.D., medical director of the adult blood and marrow stem cell transplant and cellular therapy program in the OHSU Knight Cancer Institute. (OHSU/Kristyna Wentz-Graff)